Compare
ALX Oncology Holdings Inc vs Scynexis Inc vs Rani Therapeutics Holdings, Inc. vs ProPhase Labs, Inc.
| Latest fiscal year | ALX Oncology Holdings Inc ALXO | Scynexis Inc SCYX | Rani Therapeutics Holdings, Inc. RANI | ProPhase Labs, Inc. PRPH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $20.60M | $1.63M | $4.34M |
| Revenue growth (YoY) | n/a | +449.9% | +58.9% | -35.8% |
| Gross margin | n/a | n/a | n/a | 31.9% |
| Operating margin | n/a | -78.0% | n/m | -415.4% |
| Net margin | n/a | -41.8% | n/m | -339.3% |
| Net income | -$101.69M | -$8.61M | -$40.95M | -$14.74M |
| EPS (Diluted) | -$1.90 | -$0.17 | -$0.45 | -$1.74 |
| Operating cash flow | -$84.14M | -$5.28M | -$18.71M | -$8.34M |
| Free cash flow | -$84.35M | n/a | -$18.80M | -$8.34M |
| Cash & equivalents | $16.37M | $21.26M | $18.62M | $90.0K |
| Total assets | $59.05M | $59.03M | $58.62M | $59.87M |
| Total liabilities | $33.06M | $9.65M | $17.11M | $56.36M |
| Shareholders' equity | $25.98M | $49.38M | $33.01M | $3.51M |
| Return on year-end equity | -391.4% | -17.4% | -124.1% | -420.3% |
| Shares outstanding | 54.39M | 43.54M | n/a | 8.97M |
Revenue, most recent five fiscal years
| Fiscal year | ALX Oncology Holdings Inc | Scynexis Inc | Rani Therapeutics Holdings, Inc. | ProPhase Labs, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2022-12-31 | $20.60M Ended 2025-12-31 | $1.63M Ended 2025-12-31 | $4.34M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2021-12-31 | $3.75M Ended 2024-12-31 | $1.03M Ended 2024-12-31 | $6.77M Ended 2024-12-31 |
| 2 years earlier | $1.18M Ended 2020-12-31 | $140.14M Ended 2023-12-31 | $0 Ended 2023-12-31 | $34.98M Ended 2023-12-31 |
| 3 years earlier | $4.80M Ended 2019-12-31 | $5.09M Ended 2022-12-31 | $0 Ended 2022-12-31 | $122.65M Ended 2022-12-31 |
| 4 years earlier | $2.07M Ended 2018-12-31 | $13.16M Ended 2021-12-31 | $2.72M Ended 2021-12-31 | $79.04M Ended 2021-12-31 |